Company news
Tenax Therapeutics, Inc. (NASDAQ:TENX) news
Every Tenax Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 1, 2026
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
August 29, 2026
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
July 31, 2026
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
July 2, 2026
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
May 4, 2026
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
April 22, 2026
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 10, 2026
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
March 3, 2026
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
February 4, 2026
Tenax Therapeutics : Announces Result of Prespecified Blinded Sample Size Assessment
December 18, 2025
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
December 17, 2025
Tenax Therapeutics to Participate in Upcoming Investor Conferences
November 25, 2025
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
November 6, 2025
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 3, 2025
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
September 16, 2025
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
August 28, 2025
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 25, 2025
Tenax Therapeutics Announces $25 Million Private Placement
March 5, 2025
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of P...
March 5, 2025
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
March 3, 2025
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
January 22, 2025
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 13, 2024
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 13, 2024
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
August 12, 2024
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
August 6, 2024
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved...
April 30, 2024
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
March 28, 2024
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
February 29, 2024
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
February 20, 2024
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
February 8, 2024
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hyp...
February 7, 2024
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use...
February 6, 2024
Tenax Therapeutics Announces Reverse Stock Split
December 29, 2023
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
November 17, 2023
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart ...
November 13, 2023
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction...
July 19, 2023
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosime...
May 31, 2023
Tenax Therapeutics Provides 2023 Business Update
April 12, 2023
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Eject...
March 22, 2023
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
February 3, 2023
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failur...
February 1, 2023
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
September 15, 2022
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
May 23, 2022